New drug tested for stubborn blood disorder
NCT ID NCT04669600
Summary
This study tested an experimental drug called BIVV020 in 12 adults with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system attacks platelets. The main goal was to see if BIVV020 could safely help increase and maintain platelet counts over a long period, reducing the need for other rescue treatments. Researchers closely monitored participants for over a year to check the drug's effectiveness and safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA (ITP) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number :2030002
Ostrava - Poruba, 70852, Czechia
-
Investigational Site Number :2760001
Essen, 45147, Germany
-
Investigational Site Number :5280001
Leiden, 2333 ZA, Netherlands
-
Investigational Site Number :7240001
Palma de Mallorca, 07120, Spain
-
Investigational Site Number :7240002
A Coruña, A Coruña [La Coruña], 15006, Spain
-
Investigational Site Number :7240003
Seville, 41013, Spain
-
Investigational Site Number :8260002
London, London, City of, W12 0HS, United Kingdom
-
Investigational Site Number :8400001
Washington D.C., District of Columbia, 20007, United States
-
Investigational Site Number :8400002
Tamarac, Florida, 33321, United States
Conditions
Explore the condition pages connected to this study.